July 29, 2019 — Last week’s agreement on parameters for the 2020 fiscal year federal budget is good news for the Food and Drug Administration (FDA). The greatest advantage of the deal for the White House, the Democratic leadership of the House, and the Republican leadership in the Senate, of course, is that it would […]
Read more
July 1, 2019 – Among the issues on the Food and Drug Administration’s (FDA’s) plate for the remainder of 2019 are implementing organizational changes, securing appropriations funding for 2020, modernizing clinical trial design and regulating promotional messaging, according to Nancy Bradish Myers, president, Catalyst Healthcare Consulting, who spoke at the recent Coalition for Healthcare Communication […]
Read more